Skip to main content

Table 5 Novel positron emission tomography ligands commonly used in studying cognitive disorders

From: Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

Target Ligands
Amyloid (novel ligands) [11C]6-OH-BTA-1, Pittsburgh compound B
  [11C]AZD2184
  [11C]BF-227
  [18F]Flutemetamol
  [18F]BAY94-9172, florbetaben
  [18F]AV-45, florbetapir
Tubulin associated unit [18F]THK523
Neurotransmitters
Dopamine [18F]Flurodopa: dopa decarboxylation and vesicular storage
  [18F/11C]FP-CIT and related: dopa transporter
  [11C]Raclopride: D2 receptor binding in basal ganglia
  [18F]Fallypride: D2 receptor binding in the cortex
Serotonin [11C]DASB and related: serotonin transporter
  [11C]WAY-100635 and [18F]MPPF: 5-HT1A receptors
  [18F/11C]Altanserin, [11C]MDL-100907: 5-HT2A receptors
Cholinergic [11C]MP4A and related: acetyl choline esterase activity
  [11C]Nicotine, [18F]A85380: nicotine receptors
  [11C]NMPB, [18F]FP-TZTP: muscarinergic receptors
Neuroinflammation [11C]Arachidonic acid: phospholipase enzymatic activity
  [11C]Deprenyl: astrocytic activity irreversibly binds to the astrocytic enzyme monoamine oxidase B
Microglia activation [11C]PK-11195
  [11C]DAA1106
  [11C]Vinpocetine